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Abstract
BACE1 is the rate-limiting protease in the production of synaptotoxic β-amyloid (Aβ) species and hence one of the prime 
drug targets for potential therapy of Alzheimer’s disease (AD). However, so far pharmacological BACE1 inhibition failed 
to rescue the cognitive decline in mild-to-moderate AD patients, which indicates that treatment at the symptomatic stage 
might be too late. In the current study, chronic in vivo two-photon microscopy was performed in a transgenic AD model to 
monitor the impact of pharmacological BACE1 inhibition on early β-amyloid pathology. The longitudinal approach allowed 
to assess the kinetics of individual plaques and associated presynaptic pathology, before and throughout treatment. BACE1 
inhibition could not halt but slow down progressive β-amyloid deposition and associated synaptic pathology. Notably, the 
data revealed that the initial process of plaque formation, rather than the subsequent phase of gradual plaque growth, is most 
sensitive to BACE1 inhibition. This finding of particular susceptibility of plaque formation has profound implications to 
achieve optimal therapeutic efficacy for the prospective treatment of AD.
Keywords Alzheimer’s disease · β-Amyloid plaque · In vivo two-photon microscopy · BACE1 inhibitor treatment · 
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Introduction
AD is a progressive neurodegenerative disease character-
ized by two histopathological hallmarks, namely β-amyloid 
plaques and neurofibrillary tangles [25]. Given the growing 
number of AD patients [1, 89] and the current lack of an 
effective treatment, there is an urgent need for the develop-
ment and evaluation of disease-modifying therapies. The 
β-amyloid cascade hypothesis emphasizes accumulation 
of β-amyloid peptide (Aβ) as the initial pathological event 
that ultimately leads to synapse loss and dementia [31, 
33–35]. Aβ is produced by sequential proteolytic cleavage 
of amyloid precursor protein (APP) via beta-site amyloid 
precursor protein cleaving enzyme 1 (BACE1) [23, 42, 70, 
76, 84] and γ-secretase complex [17, 69, 80]. γ-secretase 
inhibitors have exhibited toxicity problems [77, 79] because 
of on-target interference with Notch [4, 18, 19]. Congru-
ently, genetic deletion of the catalytically active subunit 
presinilin-1 (PS1) is embryonically lethal in mice [68, 81]. 
Conversely, BACE1 knock-out mice are viable and fertile. 
Recent studies have revealed mechanism-based adverse 
effects of BACE1 inhibition in animal models [16, 26, 88], 
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but these effects are relatively mild compared to γ-secretase 
inhibitor-induced deficits. Hence, BACE1 is currently one 
of the prime therapeutic targets for decreasing cerebral Aβ 
levels. However, even though BACE1 inhibitors efficiently 
lower brain Aβ levels [48, 59, 60], so far two clinical trials 
with mild-to-moderate AD patients failed due to unspecific 
side effects [60] or lack of efficacy, as documented by the 
recent failure of the phase 2/3b EPOCH trial of verubeces-
tat (ClinicalTrials.gov identifier NCT01739348). The phase 
II trial of the BACE1 inhibitor LY2886721 was suspended 
due to possible liver toxicity [60], which was ascribed to 
unspecific side effects of the drug. Some concerns were 
also raised about potential mechanism-based effects asso-
ciated with diminished BACE1 cleavage of β-galactoside 
α2,6-sialyltransferase in the liver [51, 55]. However, liver 
injury does not develop after genetic ablation of BACE1 
in mice [57] and was not reported in Merck’s phase ll/lll 
EPOCH trial of the BACE1 inhibitor verubecestat. In this 
latter trial, Merck did not report on safety signals that war-
ranted trial termination even after 18 months of treatment. 
However, the trial was ultimately suspended due to lack of 
efficacy to reduce cognitive decline in mild-to-moderate AD 
patients. Lack of success may relate to the timing of the 
therapeutic intervention. β-amyloid deposition commences 
decades before the manifestation of clinical symptoms 
[2, 41, 78]. Thus, at a stage when amyloid deposition has 
already reached an asymptote of accumulation, Aβ lower-
ing drugs might have no impact anymore. Therefore, cur-
rent trials test therapeutic intervention commencing at vari-
ous stages of the disease. In the present study, transgenic 
 APPPS1xVGLUT1Venus mice [39, 64], expressing the fluo-
rescent protein Venus in presynaptic terminals were treated 
at an early stage of β-amyloid pathology with the potent, 
blood brain barrier penetrating BACE1 inhibitor NB-360 
[63]. Since β-amyloid deposition is a dynamic process [2, 
12] in which initial plaque seed formation is followed by 
gradual plaque growth [14, 37], chronic in vivo two-photon 
imaging was performed, to monitor potential therapeutic 




NB-360 was synthesized and kindly provided by Novartis. 
The pharmacological properties of NB-360 were character-
ized previously [63]. Mice were fed ad libitum with food 
pellets containing NB-360 (0.25 g/kg, corresponding to a 
daily oral dose of 20 μmol/kg) or control pellet. To meas-
ure the impact of BACE1 inhibition on soluble Aβ levels, 
1.5 months old mice were treated for 2 weeks and sacrificed 
thereafter. For the chronic in vivo imaging experiments, 
treatment was performed from 4 months to 7 months of age.
Transgenic and mutant mice
Heterozygous APPPS1 mice coexpress human APP with 
the Swedish mutation (KM670/671NL) and mutated PS1 
(L166P) under the pan-neuron-specific Thy1-promoter 
[64]. APPPS1 mice were crossbred with homozygous 
 VGLUT1Venus knock-in mice that express the Vesicular 
GLUtamate Transporter 1 (VGLUT1), fused to the fluo-
rescent protein Venus under the endogenous VGLUT1 pro-
moter [39]. Non-transgenic APPPS1 littermates crossed with 
homozygous  VGLUT1Venus mice served as control. Mice 
were group-housed under pathogen-free conditions until 
surgery, after which they were kept single-housed. Similar 
numbers of male and female mice were used in the control 
and treatment cohort.
Statistics
For statistical analysis, GraphPad Prism 5 (GraphPad Soft-
ware, San Diego, California) was used. Data was tested for 
normal distribution using D’Agostino-Pearson omnibus K2 
test and Kolmogorov–Smirnov test. Inter-group comparisons 
were performed using two-tailed unpaired Student’s t-test. 
In the longitudinal measurements, variables were compared 
across groups using two-way ANOVA (TWA) and p values 
refer to the test of interaction unless specified otherwise. 
TWA was performed over the total range of X-axis unless 
specified otherwise. If treatment effects, genotype effects, 
time effects, or interactions were found, post hoc analyses 
were performed using Bonferroni analysis. All the results are 
presented as mean ± SEM unless specified otherwise. For 
statistical analysis, biological replicates (individual mice, 
not plaques) were considered as experimental unit. Data 
analysis was conducted in blinded fashion.
Plasma and brain homogenization and extraction
Mice were deeply anesthetized via intraperitoneal injection 
of ketamine and xylazine (130/10 mg/kg, respectively). 
Blood was collected via cardiac puncture into EDTA tubes 
(BD microtainer tubes with K2EDTA #365974) on wet ice 
and was centrifuged at 1500 g for 15 min at 4 °C. Plasma was 
obtained from the supernatant and was frozen at − 80 °C. 
Brains were isolated, quick-frozen on dry ice and stored at 
− 80 °C. Frozen murine forebrains were homogenized in 
nine volumes of ice-cold Tris-buffered saline (pH 7.4) con-
taining Complete protease inhibitor cocktail (Roche Diag-
nostics, Penzberg, Germany) using a Sonifier 450 (Branson) 
and stored in aliquots at − 80 °C. Triton X-100 soluble Aβ 
was extracted by adding Triton X-100 (final concentration 
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1%) to homogenate, incubating for 15 min on ice with vor-
texing, followed by ultracentrifugation at 100,000×g for 
15 min. The clear supernatant was diluted to a final dilution 
of 1:100 and used for analysis.
Aβ quantification
Six weeks old APPPS1 mice were fed for 2 weeks with 
food pellet containing either vehicle or NB-360 and were 
sacrificed subsequently to collect blood and brain samples. 
Aβ40 and 42 levels were determined in the forebrain and 
plasma using the electro-chemiluminescence immuno assay 
kits based on 6E10 from Meso Scale Discovery (Rockville, 
MD, USA) in either singlet or triplex format. Samples and 
standards were prepared according to the manufacturer’s 
protocols.
Protein analysis
Western Blot analysis was performed in forebrain homogen-
ates of APPPS1 mice treated for 2 weeks with NB-360 and 
sacrificed at 2 months of age. Protein concentrations were 
measured using the BCA method (B9643, Sigma-Aldrich, 
Missouri, USA). Proteins were separated under denaturing 
conditions using SDS-PAGE. Equal amounts of proteins 
denatured in Laemmli buffer (8% SDS, 40% glycerol, 10% 
β-mercaptoethanol, 0.025% bromophenol blue, 125 mM 
Tris pH 6.8) were loaded onto the gel and 10 μL of the 
Dual Xtra Prestained Protein Standard (BioRad) served 
as molecular mass marker. Proteins were separated in 8% 
SDS-PAGE gels with Tris-buffer (25 mM Tris, 190 mM gly-
cine, 0.1% SDS). After separation by SDS–PAGE, proteins 
were transferred onto polyvinylidene difluoride membranes 
(Amersham Hybond P 0.45 PVDF, GE Healthcare Life 
Science) with Tris–glycine buffer (25 mM Tris, 240 mM 
Glycine). The PVDF membranes were blocked with 6% dry-
skimmed milk (Thermo Fischer Scientific) and 0.1% Tween-
20 (A4974, 0500 AppliChem Panreac) in PBS for 30 min 
at room temperature. Transferred proteins were detected 
using enhanced chemiluminescence. First, blocked mem-
branes were incubated with primary antibodies (APP: Y188, 
ab32136, Abcam; BACE1: 5606S, Cell Signaling and Cal-
nexin: ADI-SPA-860, Enzo) diluted in PBS-T buffer (0.5% 
Tween-20 in PBS) overnight at 4 °C. After removal of the 
antibody, membranes were washed three times for 10 min at 
RT in PBS–T and subsequently incubated with horseradish 
peroxidase-coupled secondary antibody (Promega). Second-
ary antibodies were diluted in PBS-T and membranes were 
incubated for 1 h at RT followed by three washes in PBS-
T. Membranes were incubated with horseradish peroxidase 
substrate (ECL, GE Healthcare or ECL Plus, Thermo Sci-
entific) for 2 min at RT and signals were captured with the 
ImageQuant LAS 4000 biomolecular imager (GE Healthcare 
Life Science). Quantitation of protein was conducted using 
Multi Gauge software (Fujifilm). Hybridization of calnexin 
was used as a control for equal loading. Quantitative data 
were analyzed statistically by using two-tailed Student’s 
t-test.
Cranial window surgery
A cranial window was implanted over the right cortical 
hemisphere as previously reported [27, 40]. In brief, the 
mice were anesthetized with an intraperitoneal injection of 
ketamine/xylazine (130/10 mg/kg body weight; WDT/Bayer 
Health Care). Additionally, dexamethasone (20 µL at 4 mg/
mL; Sigma) was intraperitoneally administered immediately 
before surgery [40] to prevent the development of cerebral 
edema. An open skull cranial window (5 mm diameter cov-
erslip) was implanted above the somatosensory cortex (coor-
dinates of craniotomy: Bregma + 1.5 to − 3.5 mm, 3 mm 
lateral from midline) and a metal bar was attached to allow 
repositioning of the mouse during subsequent imaging ses-
sions. After surgery, mice received subcutaneous analgesic 
treatment with carprofen (7.5 mg/kg body weight; Rimadyl; 
Pfizer) and antibiotic treatment with cefotaxime (5 mg/kg 
body weight; Pharmore).
Chronic in vivo two‑photon imaging
In vivo two-photon imaging was started after a recovery 
period of 3–4 weeks. For β-amyloid staining, Methoxy-X04 
[52] was intraperitoneally injected 24 h before imaging at 
a dose of 0.5 mg/kg body weight. Throughout the imaging 
sessions, mice were anesthetized with isoflurane (1% in 95% 
 O2, 5%  CO2,  Forene®, Abbott), placed on a heating pad to 
keep body temperature at 37 °C (Fine Science Tools GmbH) 
and fixed to a custom-made holder using the glued metal 
bar. In vivo two-photon imaging was performed on a LSM 
7 MP (Carl Zeiss) equipped with GaAsP (Gallium Arsenide) 
detectors and a 20x water-immersion objective (W Plan-
Apochromat 20x/1.0 DIC, 1.0 NA, Carl Zeiss). For each 
mouse, one region of interest was reimaged at a weekly inter-
val. To resolve the presynaptic boutons, a high-resolution 3D 
stack was obtained from the  VGLUT1Venus fluorescence in 
cortical layer I at a resolution of 0.08 × 0.08 × 0.4 µm3 and 
dimensions of 283 × 283 × 60 µm3. Subsequently, a larger 
but less resolved 3D stack was obtained from the Methoxy-
X04 fluorescence at a resolution of 0.24 × 0.24 × 0.4 µm3 
and dimensions of 425 × 425 × 200 µm3. Methoxy-X04 
was excited at 750 nm by a Ti: Sa laser (MaiTai DeepSee, 
Spectra-Physics) and emission was collected below 485 nm. 
 VGLUT1Venus was excited at 915 nm and emission was col-
lected from 470 to 550 nm. In subsequent imaging sessions, 
the previously imaged volumes were identified using the 
unique blood vessel pattern, enabling precise alignment of 
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the same imaged volumes. The laser intensity was adjusted 
to keep the emitted fluorescence stable at different depths 
using the z-correction tool in the microscope control soft-
ware and also at subsequent imaging sessions.
Immunohistochemistry
Deeply anesthetized mice (130/10 mg/kg b.w. ketamine/
xylazine i.p. WDT/Bayer Health Care) were perfused with 
phosphate-buffered saline (PBS) followed by 4% formalin 
solution. Mouse brains were dissected and post-fixed in 4% 
formalin for 24 h. Fixed brains were cut into coronal 50 μm 
thick sections on a vibratome (VT1000S, Leica). Brain slices 
were permeabilized over night with 2% Triton X-100 in PBS 
and blocked for 2 h at RT with 10% normal goat serum 
(Sigma-Aldrich) in 0.3% Triton X-100 in PBS. Slices were 
then incubated with a rabbit polyclonal antibody directed 
against BACE1 (1:100; D10E5, Cell Signaling) in 0.3% 
Triton X-100 for 2 days at 4 °C. Sections were washed in 
PBS and incubated with the secondary antibody coupled to 
Alexa594 (anti-rabbit 1/500, Invitrogen) for 2 days at 4 °C. 
To detect β-amyloid fibrils, the slices were incubated for 
15 min with 10 µg/mL Methoxy-X04 in 50% ethanol and 
were washed three times with 50% ethanol at RT. Sections 
were finally washed for three times 10 min with PBS before 
mounting them on glass coverslips with fluorescence-con-
serving mounting medium (Dako).
Confocal imaging
Images were acquired with a LSM 780 confocal microscope 
(Zeiss) equipped with a 40×/1.4 oil immersion objective. 
Excitation wavelengths were 405 and 561 nm, and emission 
was collected at 410–580 nm and 585–735 nm for Meth-
oxy-X04 and BACE1, respectively. In each mouse brain, 
3-dimensional 16 bit data stacks of 1024 × 1024 × 100 pix-
els were acquired in the somatosensory cortex at a lateral 
resolution of 0.1 μm/pixel and an axial resolution of 0.2 µm/
pixel.
Analysis of 3D microscopical data
All data stacks obtained by in vivo two-photon microscopy 
were deconvoluted using AutoQuant (AutoQuantX3, Media 
Cybernetics). For quantification of amyloid plaques, presyn-
aptic boutons, presynaptic dystrophies as well as BACE1 
positive dystrophies, the 3D data stacks of fluorescence 
intensity were analyzed using custom-written MATLAB 
software. Initially, local background subtraction was per-
formed to diminish intensity variations among different 
stacks. Subsequently, a percentile-based intensity threshold 
was applied, and connected component analysis was used to 
identify contiguous clusters of voxels. This standard analysis 
was slightly modified for each of the biological readouts 
with the detailed analysis described below.
To define BACE1 positive dystrophies, the 70th percen-
tile of immunofluorescence signal was used as threshold 
for each image stack. Connected component analysis was 
applied to identify clusters of contiguous voxels, and clusters 
smaller than 1 µm3 were excluded.
For data stacks of  VGLUT1Venus fluorescence, the 75th 
percentile was used as threshold. Due to the dense arrange-
ment of VGLUT1 positive structures, applying that thresh-
old results in a web-like mask of supra-threshold voxels with 
nearby structures still merging into one another. Therefore, 
the data was further segmented morphologically by calcu-
lating the distance transformation, followed by watershed 
segmentation along minimal distance ridges. Subsequently, 
the minimal diameter as well as the distance to the closest 
plaque was obtained for each segment. To analyze the distri-
bution of minimal diameter of VGLUT1 positive structures 
as a function of plaque distance and plaque size, the minimal 
diameter was binned into 0.2 µm steps. Bouton densities in 
relation to the distance from plaques were fitted using one-
phase association curves.
• Y(d) = Y0 + (Plateau − Y0) × (1 − e–K × d), with d = dis-
tance to closest plaque and Y = bouton density.
The half-distance (ln (2)/K) was obtained as measure for 
the sphere of toxic influence of plaques on bouton density.
Amyloid plaques were identified applying the 90th per-
centile on the Methoxy-X04 fluorescence intensity data. 
Since amyloid burden typically constitutes up to 2% of brain 
volume in the imaged brain region of 7 months old APPPS1 
mice, this threshold is intentionally set to a very low level. 
It allows determining the total size of amyloid plaques, 
as opposed to thresholding operations such as using local 
contrast or half-width intensity that rather detect the dense 
plaque core. Subsequently, individual amyloid plaques were 
tracked over time. For this purpose, the image data from 
consecutive timepoints was loaded as time series in Imaris 
(Version 7.7.2, Bitplane). Plaque volumes were extracted 
by 3D surface rendering and were semi-automatically 
tracked over time using the surface tracking module of Ima-
ris. To identify events of plaque formation, plaques were 
tracked back to the first timepoint of appearance and were 
only assessed when present for at least 3 weeks, to warrant 
unambiguous distinction from background signal. Therefore, 
quantification of plaque density and formation only include 
values up to 8 weeks post-treatment even though imaging 
was performed up to 10 weeks. Correct tracking was manu-
ally checked for each amyloid plaque. For reliable determi-
nation of the actual size of each amyloid plaque, the largest 
extension in XY was determined and the radius was cal-
culated as, radius =
√
area∕휋 , assuming spherical shape of 
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plaques [37]. The radii of individual plaques were fitted with 
a monophasic association function, and radial growth rate at 
each timepoint was obtained by calculating the first deriva-
tive of the best fit. All plaques contacting the image border 
were excluded from the analysis. The distribution of presyn-
aptic boutons, presynaptic dystrophies and BACE1 positive 
dystrophies was analyzed with regards to proximity to the 
closest amyloid plaque. For this purpose, a quasi-Euclidean 
3D distance transformation was performed to identify the 
distance of every voxel to the closest plaque border. Distance 
was calculated at 1 µm resolution from the outer border of 
plaques into surrounding tissue as well as towards the inside 
of each plaque. Voxels inside plaques were assigned negative 
distance from plaque border. To quantify the pathological 
impact of each plaque separately, the 3D volume was divided 
into sectors with all voxels closest to a particular plaque 
constituting the sector of that plaque.
For the correlation of plaque formation rate with plaque 
distance, the distance to the closest already existing plaque 
was determined for each formation event at the respective 
timepoint of formation. All plaques that formed after treat-
ment onset were pooled and closest plaque distance was 
binned into 20 µm segments. For the frequency distribution 
of minimal inter-plaque distance, the distance to the closest 
plaque was determined for all plaques at week 10, and inter-
plaque distance was binned in 20 µm segments.
Results
NB‑360 potently reduces soluble Aβ levels
To assess the efficacy of the BACE1 inhibitor NB-360 
[63], APPPS1 mice [64] were fed with food pellet contain-
ing NB-360 or vehicle, starting at an age of 6 weeks. After 
2 weeks of chronic treatment, soluble Aβ40 and Aβ42 lev-
els were determined via ELISA. NB-360 treatment reduced 
soluble Aβ40 and Aβ42 levels in the forebrain by 80% and 
plasma Aβ40 levels by 70% (Fig. 1a). Consistent with pre-
vious studies [22, 63], full-length APP was significantly 
increased after BACE1 inhibition, while BACE1 levels 
remained unaltered (Supplementary Fig. 1). The experiment 
was performed before onset of β-amyloid deposition, since 
deposited Aβ might bias the measure of changes in peptide 
synthesis.
BACE1 inhibition slows down β‑amyloid deposition
We further tested whether pharmacological interference with 
Aβ generation reduces β-amyloid plaque burden and plaque-
associated synaptic pathology. In  APPPS1xVGLUT1Venus 
mice, chronic in vivo two-photon imaging of Methoxy-X04 
stained β-amyloid plaques and glutamatergic boutons was 
performed weekly in the somatosensory cortex from 3 to 
7 months of age (Fig. 1b, c). NB-360 or vehicle treatment 
was initiated at 4 months of age. In each mouse, approxi-
mately 67 individual plaques were tracked at consecutive 
imaging timepoints (Fig. 1d), and changes in size were 
quantified over time (Fig. 1e–h). In vehicle-treated mice, 
β-amyloid burden increased linearly over the imaging period 
at a rate of 0.085 ± 0.022% brain volume occupied by fibril-
lar Aβ per week. BACE1 inhibition significantly slowed 
down β-amyloid deposition by 54% (Fig. 2a). β-amyloid 
deposition progressed faster in female compared to male 
mice (Supplementary Fig. 2). This observation is in line 
with a previous study on β-amyloid deposition in 5XFAD 
mice [66] and likely caused by the presence of an estrogen 
response element in the Thy-1 promoter driving expres-
sion of APP and PS1 in these transgenic AD mice. BACE1 
inhibitor treatment had comparable impact in both genders, 
which is consistent with previous results of BACE1 haplo-
insufficiency in different genders [21]. Since the number of 
females and males was counterbalanced between treatment 
cohorts, mice of both genders were pooled for subsequent 
experiments.
BACE1 inhibition effectively lowers formation 
of new plaques
β-amyloid deposition can occur either by accretion of solu-
ble Aβ to the surface of existing plaques or via de novo 
plaque formation. BACE1 inhibition significantly reduced 
the formation rate of new plaques (Fig. 2b). Mean forma-
tion rate started to decrease in the second week of BACE1 
inhibitor treatment and reached a mean reduction by 12-fold 
between 4 to 8 weeks after treatment. After 8 weeks of 
BACE1 inhibitor treatment, plaque density was reduced by 
18.9% compared to vehicle treatment (values were normal-
ized to week 0, Fig. 2c). Measurements of plaque formation 
and density are presented only up to 8 weeks after treatment, 
since newly formed plaques have to be present for at least 3 
consecutive timepoints to warrant accurate detection.
BACE1 inhibition reduces plaque growth
Growth of individual plaques was quantified as incremental 
increase of plaque radii per week. Over the imaging period, 
plaque growth slightly decreased with time in both cohorts 
(Fig. 2d). Thus, the imaging period relates to the transition 
phase of β-amyloid deposition [14], when the plaque surface 
available for further Aβ accretion, starts to exceed the avail-
able levels of soluble Aβ [3, 12, 14, 83]. Apart from the age-
dependent decline, BACE1 inhibition significantly reduced 
plaque growth rates. Between 1 to 10 weeks after treatment, 
mean plaque growth was reduced by approximately 52% 





had formed, they did not shrink nor disappear throughout the 
treatment period. In line with a previous publication [37], 
plaque growth rates were similar for different plaque sizes 
and BACE1 inhibition reduced plaque growth, irrespective 
of plaque size (Supplementary Fig. 3a). After 10 weeks of 
chronic BACE1 inhibitor treatment, pre-existing plaques 
remained smaller and less small plaques were present (Sup-
plementary Fig. 3b).
Formation of new plaques is enhanced in vicinity 
to pre‑existing plaques
Previous studies have shown that BACE1 accumulates in 
plaque-associated presynaptic dystrophies [20, 47, 86, 87] 
and thereby locally enhances Aβ production [67]. However, 
so far it is unclear whether elevated Aβ levels within peri-
plaque dystrophies significantly potentiates extracellular 
β-amyloid deposition and whether inhibition of BACE1 
activity might break this vicious pathogenic cycle. In line 
with previous studies, our immunohistochemical analysis 
indicates that BACE1 accumulation is restricted to the vicin-
ity of plaques and was detected up to approximately 5 µm 
from plaque borders (Fig. 3a, b). In both treatment cohorts, 
local BACE1 accumulation was already evident for small 
plaques and significantly increased with plaque size, reach-
ing a maximum for plaques of approximately 10 µm radius 
(Fig. 3c). Inhibition of BACE1 activity did not reduce local 
accumulation of BACE1 protein comparing equally sized 
plaques at the end of the treatment period. To investigate 
whether BACE1 accumulation in peri-plaque dystrophies 
might exacerbate local β-amyloid deposition, we quantified 
whether de novo plaque formation is enhanced close to pre-
existing plaques. For this purpose, the distance to the closest 
plaque was calculated in all parts of the imaged brain vol-
ume (Fig. 3d) and the number of plaques that formed close 
and distant to pre-existing plaques within 1–8 weeks after 
treatment initiation was quantified (Fig. 3e). The average 
distance of brain volume to closest plaques was approxi-
mately 55 µm and reached a maximal distance of 160 µm 
(Supplementary Fig. 3c, d). In contrast, most plaques formed 
within 40 µm distance to pre-existing plaques. In vehicle-
treated mice, the rate of plaque formation within 0-20 µm 
distance from pre-existing plaques was 4.2-fold higher as 
compared to the rate at 80-100 µm distance (Fig. 3f). In 
line with this observation, short inter-plaque distances were 
significantly more frequent at the end of the imaging period 
(Supplementary Fig. 2e). In BACE1 inhibitor-treated mice, 
plaque formation was globally reduced at all distances to 
plaques and was almost exclusively restricted to the vicinity 
of pre-existing plaques.
BACE1 inhibition mitigates progression 
of presynaptic pathology
To assess, whether the beneficial impact of BACE1 inhibition 
on β-amyloid deposition mitigates synaptic pathology, the size 
and density of VGLUT1 positive structures was quantified in 
 APPPS1xVGLUT1Venus mice [39, 64]. In each mouse, approx-
imately 20 individual plaques were tracked with high resolu-
tion at consecutive imaging timepoints up to 8 weeks after 
treatment. The  VGLUT1Venus fluorescence pattern appeared 
punctate with small sphere-like presynaptic boutons distant 
from plaques and large swollen presynaptic dystrophies in 
proximity to plaques (Fig. 4a). Custom-written MATLAB 
cluster analysis was applied for automated morphological 
segmentation (Fig. 4b, upper panel), to quantify how the frac-
tion of differently sized VGLUT1 positive structures changes 
with distance to plaque border. Distant to plaques (> 30 µm 
from plaque border) approximately 20% of brain volume was 
VGLUT1 positive and the size of structures remained below 
2.0 µm (Fig. 4b, lower panel). VGLUT1 positive structures 
were classified according to their size either as boutons or 
presynaptic dystrophies. A diameter of 2.0 µm was defined as 
maximal threshold for boutons, since in wild type mice less 
than 1.0% of VGLUT1 positive structures were larger (Sup-
plementary Fig. 4a). Furthermore, a diameter of 2.0 µm also 
demarked the transition size, at which VGLUT1 positive struc-
tures became more abundant in proximity to plaques (Sup-
plementary Fig. 4b). Small plaques up to 4 µm radius did not 
develop presynaptic dystrophies but already showed a distinct 
local reduction of boutons. When plaques reached radii above 
4 µm, presynaptic dystrophies emerged within a range of up to 
approximately 10 µm around plaque borders. With increasing 
plaque size, the fraction of presynaptic dystrophies increased 
further. After plaques had reached a radius between 10 to 
14 µm, the fraction of presynaptic dystrophies remained stable. 
BACE1 inhibitor treatment did not have an apparent impact on 
the size distribution of VGLUT1 positive structures for equally 
Fig. 1  Pharmacological inhibition of BACE1 reduces soluble Aβ 
levels. a Six-week-old mice were treated for 14  days with vehicle 
or NB-360 and were sacrificed thereafter to determine Aβ levels. 
BACE1 inhibitor treatment significantly reduced the levels of Aβ40 
and Aβ42 in forebrain and plasma. Data presented as mean ± SEM 
with **p  <  0.01; ***p  <  0.001; n  =  6 mice per group; t-test. b 
In vivo two-photon imaging was performed weekly in the somatosen-
sory cortex of  APPPS1xVGLUT1Venus mice. c Mice were reimaged 
repetitively from 3 to 7 months of age. After four timepoints of base-
line imaging (at an age of 4 months), mice were administered vehi-
cle or NB-360 in food pellet until 7  months of age. d In the same 
region of interest, Methoxy-X04 stained β-amyloid plaques (cyan) 
and  VGLUT1Venus positive glutamatergic boutons (green) were 
repetitively imaged. The image series shows a plaque from a vehicle-
treated mouse. Scale bar represents 40  μm. e Time series of repre-
sentative 3D rendered plaques of the vehicle (light gray) and NB-360 
(dark gray) treated cohorts. Scale bar represents 60 μm. f, g For the 
same plaques as in e the radii at consecutive timepoints were calcu-
lated, fitted with monophasic association functions, and h growth 




sized plaques. In line with previous studies [7, 24, 32, 50, 53, 
75], the density of boutons locally decreased in proximity 
to plaques. This bouton loss became more pronounced with 
increasing plaque size, but did not differ between equally sized 
plaques of the two treatment cohorts (Fig. 4c, Supplementary 
Fig. 4c). In both treatment cohorts, the corona of presynaptic 
dystrophies became denser with increasing plaque size, but 
did not differ between equally sized plaques of both treatment 
cohorts (Fig. 4d). We then investigated whether the overall 
reduction in plaque formation and growth would beneficially 
influence the total amount of presynaptic dystrophies. Indeed, 
with time, the formation rate of plaque-associated presynaptic 
dystrophies was reduced by tenfold in BACE1 inhibitor-treated 
mice (Fig. 4e).
Discussion
The impact of BACE1 inhibitor treatment was tested at 
the transition stage of β-amyloid deposition, when initial 
plaques have already formed, but neither plaque formation 
nor plaque growth have saturated. For the majority of AD 
patients, lacking predictive genetic markers, such a stage 
might represent a realistic starting point for presymptomatic 
treatment, since β-amyloid deposition is among the earliest 
detectable pathological alterations in the AD brain [2, 71].
BACE1 inhibitor treatment reduced plaque growth 
in APPPS1 mice by twofold, and plaque formation by 
12-fold with no sign of compensatory adaptation over the 
2.5 months long treatment period. The particularly strong 
impact of BACE1 inhibitor treatment on the formation of 
new plaques might have two mechanisms. (1) Nucleation 
seed formation requires higher critical Aβ concentration 
than accretion to already existing β-amyloid fibrils [14, 36, 
38, 45]. (2) Furthermore, accumulation of BACE1 in peri-
plaque dystrophies [20, 47, 86, 87] enhances local Aβ gen-
eration [67] and thereby might exacerbate further β-amyloid 
deposition. In fact, our data and a previous study [61] show 
that pre-existing plaques potentiate local plaque formation, 
which indicates that enhanced Aβ generation within peri-
plaque dystrophies significantly contributes to extracellular 
β-amyloid deposition. Moreover, the immunohistochemical 
Fig. 2  BACE1 inhibition most effectively lowers formation of 
new plaques. a Integrated volume fraction of all β-amyloid plaques 
(TWA: Fint[13]  =  3.31, p  <  0.001; Ftime[13]  =  35.07, p  <  0.0001). 
Lines show linear regressions of the data (F-test, p < 0.01). b Mean 
rate of newly formed plaques (TWA: Fint[33]  =  1.65, p  =  0.020; 
Ftime[11] = 2.05, p = 0.026), and c kinetics of mean plaque density 
(TWA: Fint[33] = 4.41, p < 0.0001; Ftime[11] = 35.28, p < 0.0001). 
d Kinetics of mean plaque growth rates (TWA: Fint[30]  =  1.80, 
p  =  0.010; Ftime[10]  =  42.90, p  <  0.0001). Data presented as 




Fig. 3  Pre-existing plaques locally potentiate formation of new 
plaques. a BACE1 immunostainings 10  weeks after treatment initi-
ation. The green line depicts the outer plaque border as defined by 
Methoxy-X04 fluorescence, and white lines indicate 5  µm spaced 
distance rings from the plaque border. Scale bar represents 10  μm. 
b Fraction of BACE1 immuno positive brain volume at varying 
distances to the closest plaque border. c Mean fraction of BACE1 
immuno positive brain volume within 1  µm distance from plaque 
border for plaques of different radii (TWA: Fint[4] = 0.63, p = 0.643; 
Ftreatment[1] = 0.01, p = 0.912; Fradius[4] = 5.90, p < 0.001). d In all 
parts of the imaged brain volume, the distance to the closest plaque 
was determined via 3D distance transformation. In this simplified 
illustrative image, the distance representation is demonstrated only 
for plaques positioned on one Z-layer. Black concentric rings indi-
cate distance to closest plaque border with 10 µm interval. Red lines 
outline sectors of the image stack closest to one individual plaque. e 
Representative images of 3D rendered plaques before and 8  weeks 
after treatment. White plaques were already present at treatment start 
while colored plaques appeared during the treatment period. The 
colormap indicates the distance of each newly formed plaque to the 
closest border of a pre-existing plaque at the respective timepoint of 
formation. Since plaques are scattered in 3D over a depth of 200 µm, 
the inter-plaque-distance in these 2D representations occasionally 
seems smaller than inferred from the color code. Scale bar represents 
50 µm. f Mean rate of plaque formation after treatment initiation at 
varying distances to already existing plaques (TWA: Fint[4]  =  2.20, 
p  =  0.089; Ftreatment[1]  =  8.17, p  =  0.019; Fdistance[4]  =  6.17, 
p < 0.001). Data presented as mean ± SEM. b, c n = 5–6 mice (mean 
plaque number analyzed per mouse = 44). d–f n = 5–6 mice, (mean 
number of newly formed plaques analyzed per mouse = 15)
 Acta Neuropathologica
1 3
results indicate that inhibition of BACE1 activity does not 
alleviate accumulation of BACE1 protein at plaques. Conse-
quently, even though plaque formation was globally reduced 
after BACE1 inhibition, the rate of new plaque formation 
remained higher close to plaques. Thus, at a stage when 
β-amyloid pathology has commenced, pre-existing plaques 
locally aggravate further β-amyloid deposition and thereby 
hamper pharmacological intervention. Consistently, BACE1 
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inhibition only moderately reduced growth of plaques, 
while plaque formation—especially distant to pre-existing 
plaques—was almost halted in APPPS1 mice.
We quantified whether the beneficial impact of BACE1 
inhibitor treatment on β-amyloid deposition might allevi-
ate presynaptic pathology in APPPS1 mice. Consistent with 
previous work, presynaptic dystrophies and bouton loss were 
detected most notably in vicinity to plaques [7, 24, 32, 50, 
53, 75]. BACE1 inhibitor treatment reduced the overall rate 
of plaque-associated presynaptic dystrophy formation by 
approximately tenfold. However, comparing the dystrophic 
corona around plaques of similar size, we could not detect 
a significant reduction. Likewise, equally sized plaques 
exhibited similar extent of BACE1 accumulation and similar 
degree of local bouton loss in both treatment cohorts. These 
findings indicate that once neuritic plaques have formed, 
the local toxicity remains even after 2 months of chronic 
BACE1 inhibitor treatment. In line with this observation, 
elevated BACE1 levels are neither reverted in young nor old 
5XFAD mice even after prolonged BACE1 inhibition [22]. 
Thus, the overall beneficial impact of BACE1 inhibitor treat-
ment on total amount of plaque-associated presynaptic dys-
trophies seems to be a result of an overall reduced number 
and size of plaques. Considering a reduction of soluble Aβ 
levels by 80%, these data support the notion that presynaptic 
dystrophies and pathological accumulation of BACE1 are a 
response to fibrillar Aβ and not soluble Aβ species. Accord-
ingly, BACE1 levels are not enhanced in individuals with 
cerebral atherosclerosis [65], a potential marker for preclini-
cal AD and thus BACE1 levels seem to increase in parallel 
with β-amyloid deposition [56], but not before.
Apart from the treatment effect, our data provide quantita-
tive characterization on the kinetics of peri-plaque presynap-
tic dystrophy formation. Dystrophies started to emerge when 
plaques reached approximately 4 µm radius. With increasing 
plaque size, the density of presynaptic dystrophies increased, 
reaching a plateau at approximately 10 µm plaque radius. 
Interestingly, the immunohistochemical analysis indicates 
that accumulation of BACE1 in vicinity to plaques also 
reached a plateau at similar plaque size. A potential cause for 
this plateau could be that over time peri-plaque presynaptic 
dystrophies disappear due to axon loss [5]. Thus, with time, 
formation and loss of presynaptic dystrophies might reach a 
dynamic equilibrium.
Altogether, our longitudinal data imply that commenc-
ing BACE1 inhibitor treatment at the transition stage of 
β-amyloid progression effectively alleviates Aβ deposition 
and plaque-associated synaptic Aβ pathology in APPPS1 
mice. However, the in vivo microscopy approach also indi-
cates that in APPPS1 mice, BACE1 inhibitor treatment nei-
ther halted β-amyloid deposition nor cleared plaques that 
were already present at treatment initiation. Despite pro-
nounced reductions in Aβ synthesis, the extent of local bou-
ton loss, presynaptic dystrophies and pathological BACE1 
accumulation remained even after prolonged BACE1 inhibi-
tor treatment. These observations are in accordance with 
a previous study which reported lower β-amyloid burden 
in BACE1 inhibitor-treated  APPLondon transgenic mice, but 
not a reduction below baseline levels [43]. Even genetically 
halting de novo Aβ synthesis in inducible APP transgenic 
mice does not affect pre-existing Aβ burden [44]. These 
data correspond to the observation that long-term BACE1 
inhibitor treatment of Tg2576 mice only prevented memory 
decline when initiated before onset of β-amyloid deposition 
[15, 30], but neither rescued memory decline in Tg2576 
[15] nor 5XFAD mice [22] when initiated after pronounced 
β-amyloid deposition. Conversely, a previous study reported 
that BACE1 inhibitor treatment repairs pathophysiology and 
cognitive deficits in APP23xPS45 mice even when initiated 
after the development of extensive Aβ pathology [49]. Addi-
tionally, previous immunohistochemical studies reported 
that BACE1 inhibition halted Aβ deposition in APP51/16 
mice [63] or even caused plaque clearance as well as an 
attenuation of dystrophic area below the level at treatment 
initiation in Tg2576 mice [73]. However, since longitudinal 
data is lacking, it remains an open question if pre-existing 
plaques are actually cleared in these models. Especially the 
Tg2576 model is prone to large inter-animal heterogeneity 
with regard to the extent of β-amyloid deposition [13].
In this context, it is important to emphasize that APPPS1 
mice overexpress human APP with the Swedish mutation, 
which is more efficiently cleaved by BACE1 than wild type 
APP [70, 76, 82], which results in an aggressive model of 
early-onset amyloid pathology [64]. It is currently unknown 
to what extent findings in rodent models will translate to the 
human AD pathology. In AD patients, β-amyloid pathology 
progresses markedly slower and treatment can be performed 
Fig. 4  BACE1 inhibition alleviates progressive plaque-associated 
presynaptic pathology. a  VGLUT1Venus fluorescence micrographs 
for two plaques before and 8  weeks after treatment. b Segmenta-
tions of the respective images in a, with color code indicating the 
minimal diameter of individual  VGLUT1Venus positive structures. 
Magenta colored lines depict the outer plaque border and white lines 
indicate 5 µm spaced distance rings from plaque border. The cumu-
lative distributions (below) indicate the proportion change of dif-
ferently sized VGLUT1 positive structures with distance to closest 
plaque. c Quantification of the density of VGLUT1 positive boutons 
after treatment initiation at varying distances and for plaques of dif-
ferent radii. Traces were fitted with monophasic association func-
tions to obtain the half-distance as quantitative measure of the toxic 
effect. d Fraction of brain volume within 2 µm distance from plaque 
border occupied by presynaptic dystrophies for plaques of differ-
ent radii (TWA: Fint[6]  =  0.46, p  =  0.835; Ftreatment[1]  =  0.047, 
p  =  0.834; Fradius[6]  =  5.21, p  <  0.001). e Total fraction of dys-
trophic brain volume within 10  µm distance from plaque border 
(TWA: Fint[11]  =  2.29, p  =  0.016; Ftime[11]  =  12.60, p  <  0.0001). 
Lines show linear regressions of the data (F-test, ns). Data presented 
as mean ± SEM; n = 4–6 mice, (mean plaque number analyzed per 




over longer time periods than is possible within the life span 
of any rodent model. In November 2017, Merck reported 
slight reduction of β-amyloid burden below baseline by 
2–4% after 18 months long treatment of mild-to-moderate 
AD patients with the BACE1 inhibitor verubecestat (Clini-
cal Trials on Alzheimer’s Disease conference). However, 
the treatment failed to rescue the cognitive decline, and it 
remains unclear whether neuritic plaques could be cleared 
[72]. It might be worthwhile to note that treatment-related 
side effects, such as increased falling and slight reduction 
in hippocampal volume were also reported at the provided 
BACE1 inhibitor dosage [72]. Future clinical trials in pre-
symptomatic patients might finally clarify whether halting 
or even reverting β-amyloid pathology can be achieved with 
tolerable BACE1 inhibitor dosage. We interpret our data that 
BACE1 inhibitor treatment at an early stage of β-amyloid 
deposition at least slows down progression of β-amyloid 
pathology, which raises realistic hope for delaying patho-
logical progression in presymptomatic AD patients (illus-
trated in Fig. 5).
In the past, numerous substrates of BACE1 have been 
identified, including 33 neuronal proteins [54], and recent 
studies have revealed mechanism-based adverse effects of 
BACE1 inhibition in animal models [16, 26, 88]. While 
initially no adverse effects were reported in the terminated 
EPOCH trial of the BACE1 inhibitor verubecestat, only 
recently treatment-related side effects have been identified, 
such as increased falling and slight reduction in hippocampal 
volume [72]. In light of potential adverse effects of BACE1 
inhibition, it will be critical to minimize BACE1 inhibitor 
dosage as much as possible. This particularly applies for 
presymptomatic treatment that will require life-long drug 
administration, initiated at a stage when individuals are still 
cognitively normal. Furthermore, not all patients diagnosed 
with preclinical AD might finally convert to dementia stage 
during their lifetime. While pharmacological BACE1 inhi-
bition seems clinically beneficial in the context of elevated 
BACE1 and Aβ levels in brains of AD patients [28, 29, 56, 
58, 85], the unequal distribution of BACE1 close versus dis-
tant to plaques poses a major obstacle. An adequate BACE1 
inhibitor dosage, necessary to sufficiently inhibit elevated 
BACE1 activity in peri-plaque dystrophies [20, 47, 86, 
87] might cause excessive inhibition of BACE1 distant to 
plaques. Conversely, partial inhibition to ensure physiologi-
cal BACE1 activity might not suffice to break the vicious 
cycle of self-sustained Aβ generation close to plaques.
The finding of particular susceptibility of plaque forma-
tion in response to BACE1 inhibition, points to a therapeu-
tic strategy that could balance potential adverse effects and 
sufficient reduction of β-amyloid deposition. Such a com-
promise would be to aim for a level of therapeutic BACE1 
inhibition that prevents formation of new plaques rather than 
aiming for complete arrest of plaque growth. Thereby, it 
is possible that a therapeutic time window exists, in which 
pharmacological BACE1 inhibition is clinically effective 
without inducing adverse effects. In agreement with this 
notion, relatively modest but sustained reduction of Aβ lev-
els by 40% results in five- to sevenfold reduced risk of devel-
oping AD [46]. In addition, slight reduction of Aβ levels by 
12% in BACE1+/− mice reduces total Aβ deposition by 50% 
in aged mice [62].
Experimental data from mice indicate that formation of 
new plaques typically occurs in the initial stage of β-amyloid 
progression [10] and that toward later stages new plaques 
rarely form, while existing plaques continue to grow [14, 
37]. Therefore, it will be crucial to diagnose AD before 
widespread β-amyloid deposition. Since the majority of spo-
radic AD cases lack predictive genetic markers, the major 
future challenge will be to identify early AD biomarkers. 
Indeed, clinical biomarkers have already been determined 
that enable AD diagnosis several years before symptom 
onset [2, 71], thus paving the way for presymptomatic 
treatment.
β-amyloid deposition typically initiates locally at dis-
tinct sites in the brain and then gradually disperses into 
adjoining unaffected regions [6, 8–11, 74]. Therefore, in 
one individual, the stage of β-amyloid pathology might 
vary between brain regions. Our data and a previous pub-
lication [61] indicate that pre-existing plaques potentiate 
plaque formation within 50 µm radius from plaque borders. 
Thus, halting plaque formation might not stop β-amyloid 
Fig. 5  Theoretical impact of pharmacological BACE1 inhibition on 
the kinetics of β-amyloid deposition. The process of plaque forma-
tion mainly occurs in the initial stage of β-amyloid progression [10]. 
Conversely, at later stages, new plaques rarely form, while existing 
plaques continue to grow [14, 37]. However, our data indicate that 
BACE1 inhibition mainly affects formation rather than growth of 
plaques. Consequently, patients might suffer from diminishing effi-
ciency of therapeutic BACE1 inhibition during the progression of 
AD, which emphasizes the relevance of presymptomatic treatment
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progression in already affected brain regions, but could 
suffice to prevent initiation of β-amyloid pathology in 
previously unaffected regions. Therefore, it might be of 
particular importance to initiate treatment at a stage when 
only distinct brain regions are affected by initial β-amyloid 
pathology. For translation of this pharmacological strat-
egy into clinical therapy, it would be necessary to empiri-
cally determine a BACE1 inhibitor dosage that effectively 
prevents β-amyloid deposition in previously unaffected 
brain regions, e.g., by PET imaging. However, we point 
out that in this study, only a single BACE1 inhibitor dos-
age was tested at one stage of β-amyloid pathology and 
therefore these assumptions require further investigation. 
The APPPS1 model might not be optimally suited for such 
experiments since plaque formation even proceeds under 
strong pharmacological BACE1 inhibition that already 
impairs spine turnover in wild type mice [88].
In summary, we demonstrate that pharmacological 
BACE1 inhibition slows down progression of β-amyloid 
pathology in a mouse model of AD. To take advantage 
of the pronounced susceptibility of plaque formation in 
response to BACE1 inhibition, treatment should be com-
menced before widespread β-amyloid deposition. Thereby, 
it might suffice to adjust BACE1 inhibition to a level that 
keeps formation of new plaques at bay and still effectively 
delays the progression of β-amyloid pathology to AD.
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